MDGL
NASDAQMadrigal Pharmaceuticals Inc.
Price$470.74-16.64 (-3.42%)
01:30 PM06:00 PM
News · 26 weeks63-33%
2025-12-142026-06-07
Mix2390d
- Other14(61%)
- SEC Filings5(22%)
- Insider3(13%)
- Earnings1(4%)
Latest news
25 items- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate,
- PRMadrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 on Wednesday, June 10, 2026, at 11:20 A.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical ne
- INSIDERChief Medical Officer Soergel David sold $516,561 worth of shares (1,042 units at $495.74) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 10,033 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASHGrowing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles associated with cardiovascular risk, including LDL-C, ApoB and Lp(a), in a secondary analysis from the Phase 3 MAESTRO program In patients with well-compensated MASH cirrhosis (F4c), Rezdiffra improved a risk score – ANTICIPATE-NASH – that predicts the probability of experiencing severe liver-related eventsMultiple real-world analyses evaluating the use of Rezdiffra in routine clinical practice demonstrated early and sustained improvements in cardiometabolic parameters, liver-related biomarkers, and live
- INSIDERDirector Levy Richard S sold $2,928,716 worth of shares (5,682 units at $515.44) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 22,015 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 15, 2026 to 15 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate, 5
- PRMadrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension RiskSecondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)Analysis of two-year data in patients with compensated MASH cirrhosis (F4c) examines improvement in ANTICIPATE-NASH risk scores, a marker for clinically significant portal hypertensionAdditional abstracts focus on early real-world evidence with Rezdiffra and the ability of noninvasive biomarkers to predict fibrosis improvement in patients treated with Rezdiffra CONSHOHOCKEN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeut
- INSIDERChief Medical Officer Soergel David sold $435,420 worth of shares (844 units at $515.90), decreasing direct ownership by 7% to 11,075 units (SEC Form 4) to satisfy tax liability4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Madrigal Pharmaceuticals Inc.SCHEDULE 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 1, 2026 to 47 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate, op
- SECSEC Form 10-Q filed by Madrigal Pharmaceuticals Inc.10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- SECSEC Form 8-K filed by Madrigal Pharmaceuticals Inc.8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- PRMadrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate UpdatesFirst-quarter 2026 Rezdiffra® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127%As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and high patient demandAdvances pipeline with global licensing agreement for a clinical-stage siRNA asset targeting a mutation in the PNPLA3 gene, a genetically validated driver of MASHMGL-2086 (oral GLP-1) Phase 1 trial on track to initiate in 2Q26; ervogastat/resmetirom drug-drug interaction study on track to initiate in 4Q26 Reports cash, cash equivalents, restricted cash and marketable securities of $817.9 million as of March 31, 2026 Company to host
- PRArrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England Journal of Medicine demonstrated a 46% reduction in liver fat in homozygous patients and a well-tolerated safety profile Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ:MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associ
- PRMadrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH PipelineCompany advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASHPhase 1 data published in The New England Journal of Medicine demonstrated a 46% liver fat reduction in homozygous patients and a well-tolerated safety profileMadrigal's pipeline includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatment CONSHOHOCKEN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company f
- SECSEC Form 8-K filed by Madrigal Pharmaceuticals Inc.8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- SECSEC Form DEFA14A filed by Madrigal Pharmaceuticals Inc.DEFA14A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- SECSEC Form DEF 14A filed by Madrigal Pharmaceuticals Inc.DEF 14A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- PRMadrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two hou
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 12 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Madrigal Pharmaceuticals Inc.SCHEDULE 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggre
- INSIDEREVP and CFO Dier Mardi was granted 5,215 shares and sold $853,993 worth of shares (1,982 units at $430.87), increasing direct ownership by 35% to 12,490 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERPresident and CEO Sibold William John was granted 14,995 shares and sold $718,316 worth of shares (1,663 units at $431.94), increasing direct ownership by 9% to 161,829 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
MDGL FAQ
7 questionsWhat does Madrigal Pharmaceuticals Inc. do?
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.Where does MDGL stock trade?
Madrigal Pharmaceuticals Inc. (MDGL) is listed on NASDAQ.What sector and industry is MDGL in?
Madrigal Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Madrigal Pharmaceuticals Inc. go public?
Madrigal Pharmaceuticals Inc. (MDGL) completed its IPO in 2007.What are analysts saying about MDGL?
Madrigal Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-01-28.What companies are similar to MDGL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MDGL side-by-side with any of them on Quantisnow.How can I track MDGL on Quantisnow?
Quantisnow aggregates Madrigal Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDGL to receive live email and push alerts on every new disclosure.